Skip to main content
Year archive

Cantargia — 2022 filings

All 80 regulatory filings released by Cantargia (CANTA) in 2022, sourced directly from the official regulator.

80 Filings
2022 Period
2022 filings (80)
Filing Released Lang
Valberedning utsedd inför årsstämman 2023
Board/Management Information
2022-11-21 Swedish
Nomination Committee appointed ahead of 2023 Annual General Meeting
AGM Information
2022-11-21 English
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-10 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report 9M 2022
2022-11-10 English
Cantargias CAN10 visar positiva effekter i modeller av systemisk skleros i de nya data som presenteras vid ACR Convergence 2022
Regulatory Filings
2022-11-08 Swedish
Cantargia’s CAN10 demonstrates positive activity in systemic sclerosis models in new data presented at ACR Convergence 2022
Regulatory Filings
2022-11-08 English
Cantargia presents new data at SITC 2022 supporting nadunolimab’s promising antitumor clinical efficacy
Regulatory Filings
2022-11-07 English
Cantargia presenterar nya data på SITC 2022 som stödjer nadunolimabs lovande kliniska antitumöreffekter
Regulatory Filings
2022-11-07 Swedish
Cantargia når milstolpe i patientrekryteringen och fokuserar utvecklingen av nadunolimab på kommande randomiserade studier
Regulatory Filings
2022-10-14 Swedish
Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies
Regulatory Filings
2022-10-14 English
Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy
Legal Proceedings Report
2022-09-22 English
Cantargia meddelar att första patienten med icke-skivepitel NSCLC behandlats med nadunolimab, Keytruda® och cellgifter
Regulatory Filings
2022-09-22 Swedish
Cantargia: Muntlig presentation av nya prekliniska effektdata för CAN10 i systemisk skleros på ACR Convergence
Environmental & Social Information
2022-09-15 Swedish
Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence
Regulatory Filings
2022-09-15 English
Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells
Regulatory Filings
2022-09-13 English
Cantargia presenterar prekliniska data som visar unika behandlingseffekter av nadunolimab på stromaceller i bukspottkörtelcancer
Regulatory Filings
2022-09-13 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-09-02 English
Nytt antal aktier och röster i Cantargia
Declaration of Voting Results & Voting Rights Announcements
2022-08-31 Swedish
New number of shares and votes in Cantargia
Share Issue/Capital Change
2022-08-31 English
Interim / Quarterly Report 2022
Interim / Quarterly Report H2 2022
2022-08-30 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report H2 2022
2022-08-30 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-08-17 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-08-12 English
Cantargia announces final outcome of the company’s significantly oversubscribed rights issue
Capital/Financing Update
2022-08-12 English
Cantargia offentliggör slutligt utfall av bolagets väsentligt övertecknade företrädesemission
Capital/Financing Update
2022-08-12 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-08-09 English
Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis
Regulatory Filings
2022-07-25 English
Cantargia rapporterar nya prekliniska effektdata för CAN10 som stödjer utveckling i hjärtmuskelinflammation
Environmental & Social Information
2022-07-25 Swedish
Cantargia publishes prospectus and certain new financial information included in the prospectus
Capital/Financing Update
2022-07-22 English
Cantargia offentliggör prospekt samt viss ny finansiell information som återfinns i prospektet
Capital/Financing Update
2022-07-22 Swedish
Extraordinary general meeting in Cantargia AB (publ)
Share Issue/Capital Change
2022-07-21 English
Extra bolagsstämma i Cantargia AB (publ)
Capital/Financing Update
2022-07-21 Swedish
Cantargia receives USPTO Notice of Allowance for composition of matter patent on antibody CAN10
Regulatory Filings
2022-07-21 English
Cantargia erhåller Notice of Allowance från USPTO för produktpatent för antikroppen CAN10
Regulatory Filings
2022-07-21 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification
2022-07-19 English
Cantargia announces the terms of its fully covered rights issue
Share Issue/Capital Change
2022-07-18 English
Cantargia offentliggör villkoren för den fullt garanterade företrädesemissionen
Share Issue/Capital Change
2022-07-18 Swedish
Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer
Board/Management Information
2022-07-08 English
Cantargia utser Dr. Dominique Tersago till Chief Medical Officer
Board/Management Information
2022-07-08 Swedish
Kallelse till extra bolagsstämma i Cantargia AB (publ)
AGM Information
2022-06-21 Swedish
Notice of extraordinary general meeting in Cantargia AB (publ)
AGM Information
2022-06-21 English
Cantargia resolves on a fully covered rights issue of approximately SEK 250 million
Capital/Financing Update
2022-06-21 English
Cantargia beslutar om en fullt garanterad företrädesemission om cirka 250 miljoner kronor
Share Issue/Capital Change
2022-06-21 Swedish
Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
Regulatory Filings
2022-05-26 English
Cantargia: Presentationen på ASCO 2022 stärker positiva fas IIa-interimsresultat för nadunolimab i NSCLC
Earnings Release Q2 2022
2022-05-26 Swedish
Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
Regulatory Filings
2022-05-26 English
Cantargia presenterar kliniska interimsdata på ASCO 2022 som påvisar nadunolimabs potential i kombination med checkpointhämmare
Regulatory Filings
2022-05-26 Swedish
Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
Regulatory Filings
2022-05-26 English
Cantargia presenterar nya robusta data på ASCO 2022 som bekräftar lovande effekter av nadunolimab vid behandling av bukspottkörtelcancer
Regulatory Filings
2022-05-26 Swedish
Årsstämma i Cantargia AB (publ)
AGM Information
2022-05-23 Swedish
Annual General Meeting in Cantargia AB (publ)
AGM Information
2022-05-23 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-05-23 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Q1 2022
2022-05-23 English
Cantargia reports positive preclinical effects in atherosclerosis demonstrating potential of CAN10 in cardiovascular disease
Regulatory Filings
2022-05-22 English
Cantargia rapporterar positiva prekliniska effekter vid åderförkalkning vilket påvisar potentialen för CAN10 inom kardiovaskulära sjukdomar
Regulatory Filings
2022-05-22 Swedish
Regulatory Filings 2022
Regulatory Filings
2022-04-29 English
Annual Report 2021
Annual Report FY 2021
2022-04-29 English
Annual Report 2021
Annual Report FY 2021
2022-04-29 Swedish
Cantargia presenterar nya kliniska data för IL1RAP-antikroppen nadunolimab vid tre sessioner på ASCO 2022
Regulatory Filings
2022-04-27 Swedish
Cantargia to present new clinical data on lead IL1RAP antibody nadunolimab over three sessions at ASCO 2022
Regulatory Filings
2022-04-27 English
Kallelse till årsstämma i Cantargia AB (publ)
AGM Information
2022-04-22 Swedish
Notice of annual general meeting in Cantargia AB (publ)
AGM Information
2022-04-22 English
Rättelse: Cantargia förstärker ledningsgruppen inför kliniska studier i sen utvecklingsfas
Board/Management Information
2022-03-10 Swedish
Correction: Cantargia strengthens executive management in preparation for late-stage clinical development
Board/Management Information
2022-03-10 English
Cantargia rapporterar positiva prekliniska effektdata för CAN10 som visar anti-fibrotisk och anti-inflammatorisk effekt i systemisk skleros
Regulatory Filings
2022-03-01 Swedish
Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis
Regulatory Filings
2022-03-01 English
Interim / Quarterly Report 2021
Interim / Quarterly Report FY 2021
2022-02-24 Swedish
Annual Report 2021
Annual Report FY 2021
2022-02-24 English
Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023
Regulatory Filings
2022-02-22 English
Cantargia rapporterar nya lovande toxikologiresultat för CAN10 och planlägger fas I-studien till 2023
Regulatory Filings
2022-02-22 Swedish
Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study
Regulatory Filings
2022-02-04 English
Cantargia rapporterar behandling av första patienten med icke-skivepitel icke-småcellig lungcancer i ny arm i CANFOUR-studien
Regulatory Filings
2022-02-04 Swedish
Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination
Earnings Release Q2 2022
2022-02-03 English
Cantargia rapporterar positiva säkerhetsdata från kliniska studien CIRIFOUR med nadunolimab i kombination med pembrolizumab
Regulatory Filings
2022-02-03 Swedish
Cantargia rapporterar överklagande av tredje part mot EPO:s beslut till förmån för Cantargias patent
Legal Proceedings Report
2022-01-19 Swedish
Cantargia reports third party appeal against EPO decision in favor of Cantargia patent
Legal Proceedings Report
2022-01-19 English
Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study
Legal Proceedings Report
2022-01-14 English
Cantargia rapporterar behandling av första patienten med trippelnegativ bröstcancer i TRIFOUR-studien
Regulatory Filings
2022-01-14 Swedish
Cantargia tar nästa steg med nadunolimab mot bukspottkörtelcancer i PanCAN:s kliniska fas 2/3-studie Precision Promise?
Legal Proceedings Report
2022-01-03 Swedish
Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial
Regulatory Filings
2022-01-03 English